Cell Therapy CDMO Market Size, Share and Forecast by 2031

The Cell Therapy CDMO Market size is projected to reach US$ 21.92 billion by 2031 from US$ 4.12 billion in 2024. The market is expected to register a CAGR of 27.1% during 2025–2031.

Cell Therapy CDMO Market Analysis

The​‍​‌‍​‍‌​‍​‌‍​‍‌re is an increase in the number of cell therapy pipelines in research and commercial biopharma companies. Government support and regulations enhance advanced therapies. An increase in the prevalence of chronic diseases promotes innovative therapies. Advances in cellular production technology fuel market growth.

Cell Therapy CDMO Market Overview

The​‍​‌‍​‍‌​‍​‌‍​‍‌ global cell therapy CDMO market is driven by major investments in R&D in the field of cell therapy, thereby propelling the demand for outsourced R&D and manufacturing services. The rising trend in personalized and targeted therapies, such as CAR-T and other cellular therapies, triggers greater dependency on CDMOs. Technological innovations such as automation, AI, and scalable manufacturing infrastructure improve manufacturing efficiency, quality, and scalability. Harmonized policies and collaboration efforts among biotech companies and CDMOs accelerate timelines and facilitate commercialization. The rising incidence of chronic, genetic, and oncology disorders creates a need for innovative therapeutic approaches, thereby solidifying CDMOs in their pivotal position within the life sciences landscape globally.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Cell Therapy CDMO Market: Strategic Insights

Cell Therapy CDMO Market Drivers and Opportunities

Market Drivers:

• Increasing Prevalence of Chronic and Rare Diseases: The rising incidences of chronic and rare diseases increase the adoption of cell therapies, driving the growth of value-added services by CDMOs that support cell therapy manufacturing.
• Surging Outsourcing of Cell Therapy Manufacturing by Biotech and Pharma Companies: For expertise, cost efficiency, and compliance with the regulatory environments, biotech and pharmaceutical firms are outsourcing cell therapy manufacturing to CDMOs. This trend permits companies to focus on their research while reducing timelines for development and commercialization.
• Expanding Clinical Trials for Innovative Therapies: Clinical trials for novel cell-based therapies boost demand for CDMOs that provide scalable, compliant manufacturing solutions to ensure consistent quality and help therapies progress from research to market.

Market Opportunities:

• Transition to Commercial-Scale Manufacturing: As cell therapies continue to progress from clinical trials into commercial products, opportunities abound for CDMOs in providing large-scale, compliant manufacturing solutions that offer consistency in quality and rapid market entry for innovative therapies.
• Strategic Initiatives by Companies: Strategic activities pave the way for firms seeking collaborations, mergers, and partnerships with CDMOs in the utilization of specialized expertise, speeding up product development, cost reduction, and reinforcing the position in the expanding field of cell therapies.
• Geographic and Capacity Expansions: The expansion of facilities within the new regions and added capacity for production allow CDMOs to meet growing global demand, tap into emerging markets, and serve more clients with enhanced productivity without compromising regulatory compliance.

Cell Therapy CDMO Market Report Segmentation Analysis

The cell therapy CDMO market is segmented into distinct categories to provide a clearer understanding of its operations, growth potential, and current trends. Below is the standard segmentation approach used in industry reports:

By Service Type:

• Drug Development and Manufacturing: The demand for services in drug development and manufacturing is growing as Biopharma companies consider outsourcing complex cell therapies. They look for experienced companies, additional capacity, and pricing strategies to expedite product launch.
• Testing and Regulatory Services: The demand for testing and regulatory services is rising because of the high-quality criteria. The expertise of the CDMOs in safety testing, potency testing, and regulatory testing has ensured the development of therapies approved globally.
• Other Service Types: Other related services that cover the management of the supply chain, warehousing, and logistics functions include the expanding reach of cell therapy due to the special handling and cold supply chain needed in cell therapy.

By End User:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Other End Users

By Geography:

• North America
• Europe
• Asia Pacific
• South & Central America
• Middle East & Africa

Cell Therapy CDMO Market Regional Insights

The regional trends and factors influencing the Cell Therapy CDMO Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Cell Therapy CDMO Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Cell Therapy CDMO Market Report Scope

Cell Therapy CDMO Market Players Density: Understanding Its Impact on Business Dynamics

The Cell Therapy CDMO Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Cell Therapy CDMO Market Share Analysis by Geography

Asia Pacific is expected to grow the fastest in the next few years. Emerging markets in South America and the MEA have untapped opportunities for cell therapy CDMO providers to expand.

The growth of the cell therapy CDMO market varies across regions due to various factors such as increasing healthcare investments, rising chronic disease prevalence, supportive regulations, and expanding adoption of advanced cell therapies. Below is a summary of market share and trends by region:

1. North America

• Market Share: Holds a significant portion of the global market
• Key Drivers: The region leads due to advanced healthcare infrastructure, strong biotech presence, significant R&D investment, and early adoption of innovative cell therapies.
• Trends: Biotech startups and large CDMOs collaborating to expedite the commercialization of CAR-T and other cell therapies.

2. Europe

• Market Share: Substantial market share
• Key Drivers: Supportive regulatory frameworks, increasing clinical trials, and rising demand for personalized and advanced cell-based treatments.
• Trends: Use of automated and modular manufacturing platforms to enhance scalability and minimize costs of producing cell therapies.

3. Asia Pacific

• Market Share: Fastest-growing region with a rising market share every year
• Key Drivers: Growing healthcare expenditure, rising chronic disease prevalence, government initiatives, and increasing adoption of advanced cell therapies.
• Trends: Increased support by the government to have cell therapy research facilities and CDMO growth within the country.

4. South and Central America

• Market Share: Growing market with steady progress
• Key Drivers: Expanding healthcare access, rising disease burden, and increasing interest in innovative therapeutics.
• Trends: Enhancement of contract manufacturing partnerships to increase local access to innovative products.

5. Middle East and Africa

• Market Share: Although small, it is growing quickly
• Key Drivers: Improving healthcare infrastructure, government support for biotech, and rising awareness of advanced treatment options.
• Trends: The rise of specialized biomanufacturing centers and the use of public-private partnerships for the cultivation of cell therapy.

Cell Therapy CDMO Market Players Density: Understanding Its Impact on Business Dynamics

High Market Density and Competition

Competition is strong due to the presence of established players such as Lonza Group AG and WuXi AppTec Co Ltd. Regional and niche providers add to the competitive landscape across regions.

The high level of competition urges companies to stand out by offering:

• Advanced Products and Services
• Compliance with Regulatory Guidelines

Opportunities and Strategic Moves

• Rising demand for cell therapies offers CDMOs opportunities to expand capacity, enter new regions, and support commercialization.
• Companies pursue collaborations, mergers, and technological investments to enhance capabilities, streamline production, and strengthen their position in the growing cell therapy sector.

Other companies analyzed during the course of research:

1. AGC Biologics Inc.
2. Samsung Biologics Co., Ltd.
3. Cytiva
4. Novartis AG
5. OmniaBio
6. Rentschler Biopharma SE
7. Recipharm AB
8. Pfizer CentreOne
9. Almac Group
10. STEMCELL Technologies
11. Eurofins
12. Avid Bioservices
13. Curia
14. Excellos
15. uBriGene Biosciences.

Cell Therapy CDMO Market News and Recent Developments

• In March 2025, WuXi Biologics Launched the EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production. EffiX is designed to meet the industry’s demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe.
• In September 2025, Charles River Laboratories International, Inc. and Akadeum Life Sciences, a leader in cell separation technologies, announced the integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program. Charles River’s Cell Therapy Flex Platform originated as an off-the-shelf solution for Cell Therapy Process Development, providing ready-to-use platforms and protocols validated for autologous CAR-T and TCR-T cell therapies to minimize risk, lower costs, and accelerate development timelines.

Cell Therapy CDMO Market Report Coverage and Deliverables

The "Cell Therapy CDMO Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Cell therapy CDMO market size and forecast at global, regional, and country levels for all the key segments covered under the scope
• Cell therapy CDMO market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Cell therapy CDMO market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the cell therapy CDMO market
• Detailed company profiles